Abstract
A mortality gap has emerged between the United States and other high-income nations before the pandemic and was estimated to account for one in seven US deaths in 2017. International comparisons in Covid-19 mortality suggest both the number and proportion of US deaths that can be attributed to this gap should have increased during the pandemic.
Publicly available data on deaths from all causes and 2020-2021 Covid-19 death counts in the United States and five European countries, were combined with population estimates by sex and age group in these European countries to produce sex- and age-specific mortality rates. These rates are averaged and applied to the US population by sex and age-group to compare the resulting and actual US death counts.
This counterfactual reveals 892,491 excess deaths in the United States in 2021—deaths that would have been prevented had the United States achieved the average mortality rates of its main West European peers. Excess deaths doubled between 2017 and 2021, with most of the increase occurring during the pandemic (89.1% increase between 2019 and 2021). Population change contributed little to the 2017-2021 increase in excess deaths (42,317 additional deaths, 9.4% of the increase). Covid-19 mortality alone continue contributed 230,672 excess deaths in 2021 (51.2%), more than 2020, whereas other causes of deaths contributed 177,235 more excess deaths in 2021 than in 2017 (39.4% of the increase).
In 2021, excess mortality in the United States relative to its European peers accounted for 25.8% of all deaths (3,426,249), up from 15.7% in 2017. The increase was driven in part by the large share of Covid-19 deaths that are excess deaths (relative to European Covid-19 mortality rates),a proportion that has hovered around 50% but increased to 63.3% in 2021 as US vaccination rates plateaued at lower levels than in European countries. The overall increase in mortality from other causes during the pandemic increasingly separates the United States from West European countries as well.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated data and additional analyses (breakdown by age and sex)
Data Availability
All materials from other sources are publicly available.
